Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
Arcturus Therapeutics (NASDAQ: ARCT) announced that its partner, Vinbiocare, has received approval from the Vietnam Ministry of Health for a Clinical Trial Application (CTA) to proceed with a Phase 1/2/3 clinical study of ARCT-154, targeting SARS-CoV-2 variants, including Delta. The trial will enroll up to 21,000 participants and assess safety, immunogenicity, and efficacy. If successful, Emergency Use Approval (EUA) is anticipated. Preclinical data shows ARCT-154 induced strong neutralizing antibody responses to variants of concern, particularly the Delta variant.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced a collaboration with Vinbiocare Biotechnology to establish a COVID-19 vaccine manufacturing facility in Vietnam. Vinbiocare will invest $40 million upfront and manage the technology transfer necessary for production, with a capacity of up to 200 million doses annually. Arcturus will grant an exclusive license for production in Vietnam, supplying proprietary technology for the manufacturing process. This partnership aims to enhance vaccine accessibility in Vietnam and other regions.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has received approval from the UK Health Research Authority to start a Phase 2 clinical study for ARCT-810, an mRNA-based treatment for Ornithine Transcarbamylase (OTC) deficiency. This study aims to assess safety, tolerability, and efficacy in up to 24 participants over 12 weeks. The trial builds on positive Phase 1 results, highlighting ARCT-810's potential to restore urea cycle function and mitigate neurological damage in OTC deficiency patients.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for Q2 2021 on August 9, 2021, after market close. A conference call will follow at 4:30 PM ET, where investors can discuss the results. The company specializes in mRNA medicines and vaccines aimed at infectious diseases and rare conditions affecting the liver and respiratory system. Arcturus utilizes advanced technologies like LUNAR® lipid-mediated delivery and STARR™ mRNA Technology, featuring a pipeline that includes candidates for SARS-CoV-2 and Influenza vaccines.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced participation in several upcoming investor and scientific conferences. Key events include the mRNA-Based Therapeutics Summit on July 13-14, 2021, and the Ladenburg Thalmann 2021 Healthcare Conference also on July 13, followed by the Cell-Mediated Therapies for Infectious Disease Summit on July 22, 2021. This highlights Arcturus' focus on advancing its mRNA vaccine programs for various diseases. More details and links can be found on their Investor Relations page.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage company specializing in messenger RNA therapies, has announced its participation in several upcoming conferences. These include the BIO Digital 2021 on June 10, 2nd Annual RNAi-Based Therapeutics Summit on June 17, SVB Leerink CybeRx Series: Vaccine Forum on June 21, and 2021 RNA Therapeutics Symposium on June 24. Arcturus focuses on infectious disease vaccines and treatments for rare liver and respiratory diseases, showcasing a diverse pipeline and extensive patent portfolio.
Primordial Genetics announced an exclusive license agreement with Arcturus Therapeutics Holdings Inc. (ARCT) for a novel RNA polymerase enzyme, aimed at enhancing the manufacturing of long, high-quality RNAs for therapeutic use. This collaboration is expected to significantly improve the efficiency and cost-effectiveness of mRNA production, which is vital for drug and vaccine development. Primordial's technology emphasizes innovative RNA manufacturing processes that could lead to advancements in pharmaceuticals, ultimately aiming to address pressing health needs.
Arcturus Therapeutics (Nasdaq: ARCT) reported Q1 2021 financial results, noting revenue of $2.1 million, down from $2.6 million year-over-year. The company incurred a net loss of $56.3 million, reflecting an increase in operating expenses to $59.8 million, driven by higher R&D costs for its ARCT-021 COVID-19 vaccine candidate. The Phase 2 trial for ARCT-021 has completed enrollment with promising interim immunogenicity data supporting plans for a Phase 3 study. Cash reserves are strong at $466.9 million, expected to cover operations for over two years.
Arcturus Therapeutics Holdings (Nasdaq: ARCT) will announce its Q1 2021 financial results on May 10, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET on the same day. The company focuses on mRNA medicines targeting infectious diseases and rare liver and respiratory diseases. Arcturus has a diverse pipeline including vaccines for SARS-CoV-2 and influenza, as well as programs for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor and scientific conferences. Highlights include:
- Guggenheim Healthcare Talks: April 1, 2021, at 4:00 p.m. ET (Panel Discussion)
- 7th Annual Truist Securities Life Sciences Summit: May 4, 2021, at 1:50 p.m. ET (Fireside Chat)
- Genetic Vaccine Development Summit: May 20, 2021, at 1:30 p.m. ET (Presentation)
Details and presentation links are available on their website.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
